SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance
Authors:
Open Access
- 9 November 2022
- journal article
- letter
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 6 (12) , e800
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemiaCancer Cell, 2021
- Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort studyBlood Cancer Journal, 2021
- Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control studyHaematologica, 2021
- Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV‐19 COVID‐19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factorsBritish Journal of Haematology, 2021
- Myeloma patients with COVID‐19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccineBritish Journal of Haematology, 2021
- The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatmentBlood Cancer Journal, 2021
- Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myelomaNature Cancer, 2020
- Monoclonal gammopathy of undetermined significance and risk of infections: a population-based studyHaematologica, 2011
- Comparative Study of Immune Status to Infectious Agents in Elderly Patients with Multiple Myeloma, Waldenstrom's Macroglobulinemia, and Monoclonal Gammopathy of Undetermined SignificanceClinical and Vaccine Immunology, 2011
- Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based studyHaematologica, 2009